Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
MENLO PARK, Calif., May 08, 2018 -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2018.
“We have undertaken additional efforts to aggressively manage our cash as we work diligently to complete our strategic review process,” said Jay Shepard, President and CEO of Versartis, Inc. “We acknowledge the patience our shareholders have shown during this process and we are committed to providing an update as soon as we can.”
First Quarter 2018 Financial Results
For the first quarter ended March 31, 2018, Versartis reported a net loss of approximately $9.0 million, or $0.25 per share, basic and diluted, compared to a net loss for the first quarter ended March 31, 2017 of $29.7 million, or $0.85 per share, basic and diluted.
Total operating expenses for the quarter ended March 31, 2018 were $8.5 million compared to $29.7 million for the quarter ended March 31, 2017. Research and development (R&D) expenses for the quarter ended March 31, 2018 were $3.6 million, compared to $22.0 million for the quarter ended March 31, 2017. The decrease in R&D expenses was primarily due to the termination of clinical and manufacturing related contracts that supported the company’s Phase 3 clinical trials for somavaratan following the Phase 3 VELOCITY trial failing to meet its primary endpoint.
General and administrative (G&A) expenses were $4.9 million for the quarter ended March 31, 2018 compared to $7.7 million for the quarter ended March 31, 2017. The decrease in G&A expenses was primarily due to the reduction in workforce and our continued efforts to reduce consulting and professional services expenses following the Phase 3 VELOCITY trial failing to meet its primary endpoint.
Total operating expenses for the quarter ended March 31, 2018 include non-cash stock-based compensation expense of $2.8 million compared to $3.9 million of non-cash stock-based compensation expense for the quarter ended March 31, 2017.
Cash, cash equivalents, and short-term investments were $74.7 million as of March 31, 2018.
Contacts:
Kevin Haas
VP, Finance
(650) 963-8595
[email protected]
Versartis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share amounts)
| Three Months Ended | |||||||
| March 31, | |||||||
| 2018 | 2017 | ||||||
| Operating expenses | |||||||
| Research and development | $ | 3,600 | $ | 22,004 | |||
| General and administrative | 4,917 | 7,656 | |||||
| Total operating expenses | 8,517 | 29,660 | |||||
| Loss from operations | (8,517 | ) | (29,660 | ) | |||
| Interest income | 193 | 199 | |||||
| Other income (expense), net | (657 | ) | (261 | ) | |||
| Net loss | (8,981 | ) | (29,722 | ) | |||
| Net loss per share- basic and diluted | $ | (0.25 | ) | $ | (0.85 | ) | |
| Weighted-average common shares used to compute basic and diluted net loss per share | 36,019 | 35,004 | |||||
Versartis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
| March 31, | December 31, | ||||||
| 2018 | 2017 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 74,686 | $ | 81,146 | |||
| Other assets | 3,594 | 3,743 | |||||
| Build-to-suit lease asset | 8,829 | 8,888 | |||||
| Total assets | $ | 87,109 | $ | 93,777 | |||
| Liabilities and stockholders' equity: | |||||||
| Accounts payable and other current liabilities | $ | 3,535 | $ | 5,593 | |||
| Build-to-suit lease obligation | 6,944 | 5,428 | |||||
| Total liabilities | 10,479 | 11,021 | |||||
| Total stockholders' equity | 76,630 | 82,756 | |||||
| Total liabilities and stockholders’ equity | $ | 87,109 | $ | 93,777 | |||
